U.S. Peptide Therapeutics (Retail Side) Market (2025 - 2033)

U.S. Peptide Therapeutics (Retail Side) Market Summary

The U.S. peptide therapeutics (retail side) market size was estimated at USD 103.66 billion in 2024 and is expected to reach USD 336.12 billion by 2033, growing at a CAGR of 12.77% from 2025 to 2033. The increasing number of pediatric patients affected by these conditions, coupled with their widespread occurrence in low-income regions, highlights the need for affordable and effective treatment options. In addition, the increasing number of pediatric patients affected by these conditions, coupled with their widespread occurrence in low-income regions, underscores the need for affordable and effective treatment options.

Rising Prevalence of Obesity and Type 2 Diabetes Fueling Demand for GLP-1 Therapies

The increase in obesity and type 2 diabetes in the U.S. is driving demand for GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound). These medications enhance glycemic control and promote weight loss, making them effective for managing these chronic conditions. Patient awareness and physician preference are boosting their adoption. A 2024 JAMA Network Open study showed that spending on GLP-1 therapies grew from USD 13.7 billion in 2018 to over USD 71.7 billion in 2023, with retail pharmacies accounting for more than 70% of this increase. In 2024, tirzepatide's Zepbound reached USD 4.9 billion in sales, while Wegovy and Saxenda together generated USD 9.9 billion.

Advancements in Peptide Therapeutics Enhancing Patient Convenience and Market Adoption

Innovation in peptide therapeutics is changing the patient experience by offering more convenient formats and broadening therapeutic options. FDA approvals for next-generation peptides such as dual agonists, once-weekly injectables, oral peptide pills, and generic/biosimilar versions are boosting the appeal of these drugs for both prescribers and patients. These advancements lessen the administration burden and enhance adherence, making them ideal for long-term outpatient use and retail dispensing. For example, according to the U.S. FDA in 2023, Eli Lilly’s tirzepatide (Zepbound) was approved for weight management after its success in treating diabetes, while Novo Nordisk’s Rybelsus (oral semaglutide) reached USD 1.7 billion in U.S. sales in 2022-demonstrating strong market acceptance of injection-free options.

Expansion of Consumer-Centric Channels for Peptide Therapy Delivery

The shift toward consumer-friendly healthcare delivery is fueling growth in the market. Traditional retail pharmacies (such as CVS, Walgreens, Walmart) and emerging telehealth platforms (such as Amazon Pharmacy, Ro, Hims & Hers) are increasingly offering peptide therapies either through prescription fulfillment or integrated consultation services. According to Eli Lilly in 2024, the company launched LillyDirect, a direct-to-consumer telehealth platform that allows patients to receive Zepbound and other peptide therapies at home. Novo Nordisk partnered with Ro and Hims & Hers to offer Wegovy at a discounted USD 499/month price for uninsured users, down from its retail list price of USD 1,349. Amazon Pharmacy, meanwhile, expanded GLP-1 fulfillment services across the country, with integrated pharmacist support and auto-refill capabilities.

Pricing Analysis in Online vs. Offline Channels

• Online Pricing Models Driven by Transparency and Accessibility: Online channels-such as Ro, Hims, AgelessRx, and other telemedicine clinics-operate on direct-to-consumer (DTC) models. These services typically charge out-of-pocket and focus on subscription pricing for ease and transparency. A patient pays a monthly fee that covers the physician consultation, medication (often compounded), follow-up support, and shipping. Popular pricing ranges are USD 200 to USD 400/month, depending on the peptide, formulation, and dosage.

• Offline Pricing Models Rely on Insurance and Manufacturer Coupons: Offline channels-including major pharmacy chains such as CVS, Walgreens, and Walmart-operate within the traditional healthcare reimbursement structure. For FDA-approved peptide drugs, retail list prices can be prohibitively high without insurance. However, those who meet medical necessity criteria can often access therapy at significantly reduced copay levels.

According to VaccineAlliance.org in 2024, offline semaglutide pricing without insurance ranges from USD 900 to USD 1,350 per month, while Novo Nordisk offers eligible patients a direct cash price of USD 499 per month at certain partner pharmacies. However, such programs come with eligibility restrictions and are not available for all indications (e.g., weight loss may not be covered unless BMI thresholds are met).

Comparative Pricing Table - U.S. Peptide Therapeutics

Source: VaccineAlliance.org, NutritionNC, Secondary Analysis Grand View Research Analysis

Market Concentration & Characteristics

The chart below illustrates the relationship between industry concentration, industry characteristics, and industry participants. The X-axis represents the level of market concentration, ranging from low to high. The Y-axis represents various market characteristics, including industry competition, degree of innovation, level of mergers & acquisition activities, regulatory impact, product substitutes, and regional expansion.

Innovations include the evolution of drug formulations from traditional injectables to oral tablets and long-acting depot systems are improving convenience and accessibility for patients, making peptides more compatible with modern outpatient care. At the same time, the introduction of biosimilars and generics across key therapeutic categories is reducing price barriers and expanding treatment to broader population segments. For instance, Eli Lilly’s 2023 launch of Ngenla (somatrogon-ghla), a once-weekly growth hormone analog, provided an alternative to daily injections, improving pediatric adherence rates.

The market saw notable consolidations as larger companies are aimed to expand their reach and capabilities. For instance, in February 2025, Hims & Hers acquired a U.S.-based peptide production facility in California to bolster its domestic supply chain and improve the consistent delivery of personalized peptide-based medications. Melissa Baird, COO of Hims & Hers said:

“The future of healthcare must be centered on the customer, which is why our operational structure is built to scale personalized care to more individuals at the highest standard of quality and safety, and with a focus on long-term consistency and availability.”

The FDA's classification of peptide therapies as biologics or drugs affects approval timelines, manufacturing requirements, and labelling, often resulting in higher development and compliance costs. This, in turn, influences retail pricing strategies and availability. For instance, GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound), which are peptide-based therapies for weight loss and diabetes, are subject to stringent regulatory oversight due to their biologic nature and high-demand profile.

The industry is experiencing significant expansion, driven by a combination of clinical innovation, increasing chronic disease prevalence, and favorable regulatory pathways. The FDA approval of Lutathera (lutetium Lu 177 dotatate) for gastroenteropancreatic neuroendocrine tumors and Zegalogue (dasiglucagon) for severe hypoglycemia reflect the growing acceptance and therapeutic potential of peptide drugs. Pharmaceutical companies are heavily investing in R&D, with firms like Amgen, Eli Lilly, and Ipsen expanding their peptide-based pipelines through both internal development and strategic acquisitions. In addition, the growing trend of personalized medicine and biologics has opened new niches for targeted peptide therapies.

Peptide Type Insights

The GLP-1 peptides segment dominated the market in 2024, holding a 43.32% share, and is expected to grow at the fastest CAGR during the forecast period. The market is mainly driven by the rising prevalence of type 2 diabetes and obesity, two major public health challenges in the country. Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and liraglutide, have shown strong effectiveness in controlling blood sugar levels and promoting significant weight loss, making them increasingly favored by both healthcare providers and patients. Additionally, the expansion of FDA-approved uses-including obesity treatment and cardiovascular risk reduction-has broadened the patient population. Growing acceptance by payers and insurance coverage for chronic weight management therapies, along with increased direct-to-consumer marketing, have further boosted demand. Furthermore, innovations in delivery methods, such as weekly injectables and oral options, are enhancing patient adherence and convenience, which accelerates market adoption. Overall, the segment benefits from proven clinical results, regulatory backing, and a rising societal focus on managing chronic diseases.

The wellness/longevity/healthspan peptides segment is anticipated to grow at the significant CAGR during the forecast period. This is driven by aging population, particularly among baby boomers and Gen X, is fueling demand for therapies that not only treat disease but also enhance vitality, delay aging, and improve quality of life. These peptides-such as growth hormone-releasing peptides (GHRPs), thymosin alpha-1, and MOTS-c-are gaining attention for their roles in cell regeneration, metabolic health, immune modulation, and muscle preservation. In addition, the rising popularity of personalized medicine and preventive healthcare is creating a receptive market for peptide-based interventions that promise long-term wellness rather than reactive treatment. The segment also benefits from growing consumer awareness through longevity clinics, biohacking communities, and direct-to-consumer peptide brands, which are normalizing the use of such therapeutics.

Therapeutics Type Insights

The innovative (branded) peptides segment led the market in 2024, capturing over 43.52% of the market share. This represents a high-value therapeutic area in the U.S., characterized by its ability to precisely target biological sites with minimal off-target effects. These peptides are synthetically engineered, often based on endogenous hormone sequences, and are designed for improved stability, bioavailability, and receptor selectivity. They are used across various therapeutic fields, including oncology, endocrinology, infectious diseases, cardiovascular conditions, and metabolic disorders. Unlike generic peptides or biosimilars, branded peptides benefit from exclusivity protections and distinct clinical positioning due to their novel mechanisms or delivery methods. In May 2025, Fujifilm published an article detailing the successful validation of peptide-oligonucleotide conjugates with enhanced cancer cell-targeting capabilities. The approach utilizes cyclic peptides from Fujifilm’s proprietary mRNA display library to improve delivery of oligonucleotides through integrin-specific binding.

The biosimilar peptides segment is expected to grow at a significant CAGR during the forecast period. This category combines traditional generics and biologics, focusing on complex peptide-based drugs that aim to replicate the safety, efficacy, and quality of reference drugs. Although not classified as biologics, longer or complex peptides produced through recombinant or semi-synthetic methods are increasingly developed as biosimilars and undergo rigorous comparability assessments. An article in Cancer Biology & Medicine highlighted the role of peptide-based therapies, such as somatostatin analogs and peptide receptor radionuclide therapy (PRRT), in treating advanced neuroendocrine neoplasms, especially well-differentiated NETs. Despite their benefits in low-grade tumors, challenges like limited investment and a lack of phase III data hinder progress in this area.

Indication Insights

The type 2 diabetes segment dominated the market in 2024 with over 25.79% share. This is due to the widespread use of GLP-1 receptor agonists. These peptide-based drugs, like semaglutide and dulaglutide, are popular for their dual benefits of controlling blood sugar and reducing weight. Retail pharmacies play a key role in distributing these treatments because of their chronic use and the increasing demand among outpatient populations for easy access and refills. In August 2023, researchers at Syracuse University co-developed GEP44, a new 44-amino acid peptide that lowers blood glucose, suppresses appetite, and boosts energy expenditure. Designed for weekly injections, GEP44 could outperform current GLP-1 drugs by encouraging insulin production and reducing side effects. The compound is aimed at future commercialization for treating type 2 diabetes and metabolic disorders.

The obesity / weight management segment is expected to grow at a significant CAGR during the forecast period, driven by the increasing clinical recognition of obesity as a chronic, treatable disease rather than a lifestyle issue, which has expanded insurance coverage and public health support. Retail pharmacies play a vital role in dispensing peptide-based weight loss drugs, especially GLP-1 receptor agonists like semaglutide, approved for both diabetes and obesity indications. In June 2025, at the ADA 85th Scientific Sessions, phase 3 results from REDEFINE 1 and 2 confirmed that once-weekly CagriSema resulted in significant weight loss in adults with and without type 2 diabetes. Participants lost up to 22.7% of body weight in REDEFINE 1 and 15.7% in REDEFINE 2 with full adherence. As a dual agonist combining semaglutide and cagrilintide, CagriSema showed strong efficacy in controlling appetite and glucose, establishing it as a next-generation treatment for obesity and diabetes.

Route of Administration Insights

The parenteral segment dominated the market in 2024 with a share of over 33.31%. This growth is mainly due to its proven ability to deliver peptides with high bioavailability and quick systemic absorption. Because peptides are inherently unstable in the gastrointestinal tract, parenteral methods such as subcutaneous, intramuscular, and intravenous injections remain the most reliable way to ensure therapeutic effectiveness. This route is especially important in acute care and for peptides with narrow therapeutic windows or rapid degradation rates. In March 2025, Signal Transduction and Targeted Therapy reviewed peptide drug development, highlighting the continued dominance of parenteral delivery.

The nasal segment is expected to grow at a significant CAGR during the forecast period due to its ability to deliver peptides systemically through the highly vascularized nasal mucosa while bypassing first-pass hepatic metabolism. The nasal route also offers the potential for direct nose-to-brain transport, which is a particularly attractive mechanism for neuroactive peptides under investigation. In April 2025, the FDA approved Neurelis' VALTOCO (diazepam nasal spray) for children aged 2 to 5 with seizure clusters, extending its prior indication. The product utilizes INTRAVAIL technology for noninvasive intranasal delivery and retains orphan drug exclusivity. Clinical studies confirmed its safety, efficacy, and ease of use, addressing longstanding limitations of rectal diazepam in pediatric seizure management.

Distribution Channel Insights

The offline retail pharmacies segment held a significant share of 38.51% in 2024. This growth is driven by its offering of in-person dispensing through licensed facilities. This segment supports the delivery of a broad spectrum of peptide drugs, ranging from widely prescribed generics to high-cost, regulated formulations. Its physical infrastructure enables direct pharmacist-patient interactions, enhances treatment adherence, and ensures compliance with controlled storage or handling requirements for selecting peptides. In May 2025, Evernorth announced the expansion of its GLP-1 care model with the launch of EnReachRx, integrating retail pharmacies into a high-touch clinical support network. Participating in retail and home delivery pharmacies will dispense GLP-1 prescriptions and offer patient education, dose optimization, and adherence support.

Online pharmacies are expected to grow at a significant CAGR during the forecast period. This growth is fueled by providing patients with easy mail-order access to prescribed products. These platforms are well-suited for chronic-use peptides, particularly those used in metabolic, endocrine, and hormone-regulating conditions where repeat prescriptions are common. Their digital infrastructure supports automated refills, direct-to-door delivery, and transparent pricing, appealing to patients seeking privacy, affordability, and consistent treatment access. In April 2025, the Journal of Medicine, Surgery, and Public Health examined 19 online listings for GLP-1 agonists, including compounded semaglutide, and found that 94.7% of platforms offered remote access without direct interaction with a physician.

Key U.S. Peptide Therapeutics (Retail Side) Company Insights

The U.S. peptide therapeutics market is moderately fragmented, comprising a mix of established retail pharmacy giants and emerging telehealth-enabled providers. Key players such as CVS Health, Walgreens Boots Alliance, Walmart Inc., The Kroger Co., and Costco Wholesale Corporation dominate the market with extensive pharmacy networks, specialty pharmacy services, and growing telehealth offerings to dispense peptide-based therapies. These companies are actively expanding their peptide therapy presence through partnerships with telehealth platforms, formulary additions of GLP-1 drugs, and affordable compounded peptide options to strengthen their competitive positioning and improve nationwide access.

Recent Developments

• In June 2024, Mark Cuban’s Cost-Plus Drug Company partnered with telehealth provider 9amHealth to integrate affordable obesity medications including generic GLP‑1 injectables like generic Victoza and branded options alongside comprehensive cardiometabolic care, into employer-sponsored plans.

• In May 2024, Hims & Hers started offering compounded GLP‑1 injections (same active ingredient as Ozempic/Wegovy) starting at $199/month, alongside oral weight-loss kits-aiming to enhance affordability and access via its telehealth platform.

• In April 2024, Costco, launched weight-loss program for members in partnership with Sesamea that includes access to GLP‑1 medications such as Ozempic and Wegovy through telehealth consultations, for a USD 179 three-month subscription-excluding drug costs.

U.S. Peptide Therapeutics (Retail Side) Market